HAVCR2 and neoplasm: evaluated the immune biomarkers of paired pre- and post-NAC tumor samples in the tumor (no-pathologic complete response, no-pCR) or tumor bed area (pCR), and found that Tim-3 positivity (≥ 1%) was significantly increased after NAC with increases occurring more frequently in no-pCR than in pCR TNBC patients (51.4% vs 31%) (61).